RayzeBio, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2026-12Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- Phase 1Recruitingreadout ~2027-02Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- Phase 1Active Not Recruitingreadout ~2027-07Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
- Phase 1/2Active Not Recruitingreadout ~2028-10Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Phase 1/2Recruitingreadout ~2030-06Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent0 acquisitions7 disposalsnet −13.4M shares · last 7
| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Viking Global Investors Lp10% owner | Feb 26, 2024 | J | 4.9M | — |
| Viking Global Investors Lp10% owner | Feb 26, 2024 | J | 4.9M | — |
| Heyman Richard A.Director | Feb 26, 2024 | D | 367,446 | $62.50 |
| Katabi MahaDirector | Feb 26, 2024 | D | 1.2M | $62.50 |
| Moran SusanOfficer — CHIEF MEDICAL OFFICER | Feb 26, 2024 | D | 323,455 | $62.50 |
| Kush ArvindOfficer — CHIEF FINANCIAL OFFICER | Feb 26, 2024 | D | 78,433 | $62.50 |
| Song KennethOfficer — PRESIDENT AND CHIEF EXECUTIVE | Feb 26, 2024 | D | 1.6M | $62.50 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsFeb 26, 2024
- Entered a material agreement · Director / officer change · Regulation FD disclosureDec 26, 2023
- Results of operationsNov 13, 2023
- Director / officer changeNov 1, 2023
- Amended charter or bylaws · Other material eventSep 19, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.